Today announced it will be in attendance at the Healthcare Week taking place together with the J.P. Morgan Healthcare Conference in San Francisco. The conference is one of the industry’s largest conferences of the year.
Today announced the signing of a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities.
Today announced it will be participating in an Industry panel discussion at the 7th Annual Microbiome Connect USA 2022 Summit taking place between November 16-17, 2022, in Boston, MA.
This addition to Biomica’s scientific expertise will support the company’s upcoming steps in its immuno-oncology clinical development program
First patient was dosed in its Phase I clinical trial that is designed primarily to evaluate the safety and tolerability of Biomica’s microbiome-based immuno-oncology drug candidate, BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in patients with either non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC).
Proof of Concept (POC) in-human trial to take place at Rambam Health Care Campus in Israel throughout 2022
Today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7, 2022, in Amsterdam, Netherlands.
Dr. Elran Haber to participate in the Industry Leaders opening panel at this premier Microbiome conference
Today announced it will be presenting at the 2022 ASCO Annual Meeting, a conference taking place in Chicago, IL from June 3 to 7, 2022.
